The first 4 pages, shown as text so search engines and readers can find this document.
Page 1
clinical practice
Valerie e Stott
MD, MSc, CCFP, is Senior Consultant,
Department of Family Medicine, Shaikh
Khalifa Medical City, Abu Dhabi, United Arab
Emirates.
Simon Stilgoe
MBChB, LRCP, LRCS, LRCP&S,
DipFamMed, is a general practitioner,
Booleroo Centre, South Australia.
Mark l Stroud
MBBS, MPH+TM, DipRACOG, FRACGP, is Senior
Consultant, Department of Family Medicine Shaikh
Khalifa Medical City, Abu Dhabi, United Arab
Emirates. purpose@tpg.com.au
Vitamin D
A review
Historically, vitamin D denoted a constituent of cod liver
oil, which cured rickets.1 it also prevented rickets in children
and osteomalacia in adults. More recently, other actions of
vitamin D have been discovered in addition to its crucial role
in calcium homeostasis.
Most body tissues have receptors for 1,25[OH]2 vitamin D (calcitriol,
1,25[OH]2D). Vitamin D is produced in the skin or ingested. After
hepatic hydroxylation, 25[OH] vitamin D (calcidiol, 25[OH]D) is further
hydroxylated in the kidneys to 1,25[OH]2D to exert its endocrine effect
on bone, kidneys and intestine.
This activated form acts at the cell nucleus (gene upregulation)
and cell membrane (rapid response) in over 30 tissues and organs,2
targeting over 200 genes.3 Examples of gene upregulation include
the above endocrine actions and additional paracrine actions when
tissues, under cytokine control, locally hydroxylate 25[OH]D to
1,25[OH]2D to modulate immune function, cell proliferation and
cell differentiation.4,5
Rapid response actions of vitamin D include promoting the
intestinal absorption of calcium, the secretion of insulin, the rapid
migration of endothelial cells and some osteoblast cell functions.2
the importance of vitamin D
Vitamin D is important for muscle and bone health. A prospective
population based study in the Netherlands showed increased loss
of muscle strength and mass with aging in those with low vitamin
D levels.6 Vitamin D deficiency is associated with cortical bone
loss,1 increased bone turnover,7 and increased parathyroid hormone
levels,5 predisposing to osteoporosis.8 Vitamin D supplementation
increases bone density in established deficiency.9 A study in the United
Kingdom found vitamin D reduced the risk of fracture in a prospective,
randomised, double blinded community based trial.10 An interventional
study in Saudi Arabia found a 95% improvement in symptoms related
to idiopathic low back pain following treatment with vitamin D.11
Vitamin D deficiency has associations with:
• cardiovascular disease12
• insulin resistance and β-cell dysfunction13,14
Background
Vitamin D status affects musculoskeletal health. More recently, the
nonmusculoskeletal actions of vitamin D have become increasingly
documented including endocrine effect on kidneys and intestine,
local autocrine effects on cell differentiation, proliferation and
immune modulation, and cell membrane effects including promotion
of the intestinal absorption of calcium and the secretion of insulin.
Objective
This article discusses the actions, sources and measurement of
vitamin D, and the treatment of established deficiency. It explores
what is known about vitamin D, what remains to be discovered, and
how clinicians should manage their patients in the interim.
Discussion
Vitamin D is produced by the same solar radiation that causes skin
cancer and aging. Levels in breast milk are low in vitamin depleted
breastfeeding women. Despite these realities, there is an opportunity
to use existing public health messages to treat the widespread
deficiency of vitamin D.
1002 reprinted from auStralian FaMily pHySician Vol. 37, No. 12, December 2008
Page 2
Oula alhabian
MD, ABFM, is Senior Consultant, Department of
Family Medicine, Shaikh Khalifa Medical City,
Abu Dhabi, United Arab Emirates.
Khaled Salman
MB, BCh, MSc, MD, is Specialist, Department of Family
Medicine, Shaikh Khalifa Medical City, Abu Dhabi, United
Arab Emirates, and Senior Lecturer, Department of Family
Medicine, Suez Canal University, Egypt.
• the development of autoimmune disease (including type 1 diabetes,
rheumatoid arthritis and multiple sclerosis), and
• colon, breast and prostate cancers.4,15
There is experimental evidence in animals that fetal deprivation produced
(permanent) neurodevelopmental change16 and in vitro evidence that
certain human antimicrobial responses are vitamin D dependent.17
Additionally, a prospective interventional study noted increased mood
with vitamin D supplementation,18 and a prospective randomised trial
noted a reduced nonskin cancer risk with vitamin D supplementation.19
These associations and results merit further research.
Sources of vitamin D
Vitamin D is found in two forms: vitamin D3 – c(h)olecalciferol,
occurring in humans and animals; and vitamin D2 – ergocalciferol,
occurring in plants. Both forms have been commercially synthesised.
Dietary sources
Food sources include:
• fatty fish (eg. herring, mackerel, sardines, tuna, salmon)
• eggs, and
• fortified foods.
Mandatory fortification of margarine and edible oil spreads occurs in
Australia. Voluntary fortification of other foods also occurs, however,
overall, dietary intake of vitamin D is low. Adequate intake of vitamin
D is unlikely to be achieved purely through dietary means, particularly
in those at high risk.
Table 1 summarises the recommended daily intake of vitamin D.
Upper levels of dietary intake are currently 1000 IU/day for infants
(0–12 months) and 3200 IU/day for all other ages and for pregnant or
lactating women.20
Sunlight exposure
The main source of vitamin D is exposure to sunlight. Approximately
90% of vitamin D is obtained this way and most Australians receive
their vitamin D requirements from the sun. At comparible latitudes,
higher UV levels have been found in the southern hemisphere.20 In
many people, adequate sunlight exposure will maintain adequate
25(OH)D serum levels. The skin uses ultraviolet B (UVB) light (280–315
nm wavelength) to form previtamin D3 from 7-dehydrocholesterol (the
immediate precursor of cholesterol). Previtamin D3 changes in the skin
to vitamin D3, which has a serum half life of 2–3 weeks. Vitamin D3
production in the skin is limited to 10 000–20 000 IU/day.3 Serum levels
of 25[OH]D plateau at about 150 nmol/L as UVB inactivates the excess
cutaneous previtamin and vitamin.21 Vitamin D binding protein transports
vitamin D, the active hormone and its metabolites in the circulation.
Skin production of vitamin D depends on:
• the amount of UVB energy (eg. latitude, season, time of day, cloud
cover)
• amount of skin exposed
• duration of exposure, and
• skin type.
Certain medications can increase or decrease 25[OH]D metabolism.22,23
Table 1. Adequate daily dietary intake of vitamin D by age
age adequate dietary
intake20
Supplementation
recommended?20
regular sunlight sufficient?#
0–12 months 200 IU Yes
1–18 years 400 IU Yes
19–50 years 200 IU Possibly
51–70 years 400 IU Possibly not
>70 years 600 IU Probably not
Institutionalised or housebound elderly Yes, 400–1000 IU No, consider screening
Pregnant women 200 IU Consider screening
Pregnant women, limited sunlight 400 IU Consider screening
Lactating women 200 IU Consider supplementation* Yes, but consider screening*
Breastfed child 200 IU Yes
Breastfed child at risk (mother dark
skinned and/or veiled)
Yes, 400 IU for first 12 months Possibly not
* Further supplementation may be considered to increase vitamin D content in milk33
# Indicates whether regular sufficient sun exposure is likely to be adequate to maintain vitamin D levels
reprinted from auStralian FaMily pHySician Vol. 37, No. 12, December 2008 1003
Page 3
Vitamin D – a reviewclinical practice
Screening
People at risk of significant deficiency include:
• the institutionalised or housebound9
• those with sun avoidant behaviour
• refugees24
• those with coeliac disease25 (or other malabsorbtive conditions)
• those from areas of high vitamin D deficiency prevalence
• those in whom osteoporosis therapy is considered
• those with chronic idiopathic musculoskeletal pain, and
• pregnant women (particularly if dark skinned or veiled).26
The type of assay is important with different methods giving differing
results, particularly at higher serum levels. Liquid chromatography is
the criterion standard.15
treatment
The current recommended daily intake of vitamin D is adequate for
bone health. Our total requirement for vitamin D (sun exposure and
dietary intake) is about 4000 IU/day to keep 25(OH)D levels above
100 nmol/L.27
The tolerable upper limit of ingested vitamin D for adults will
depend on sun exposure and is currently being debated.28–30 The
tolerable upper limit might be as high as 10 000 IU/day, however current
recommendations are significantly lower (Table 1). The level of 25[OH]D
causing toxicity in healthy adults is also debated but probably occurs at
levels >500 nmol/L.28,30 Hypercalciuria occurs before hypercalcemia.1
In Australia, megadose administrations of vitamin D3 have been
described,8 including 100 000 IU orally every 4 months10 and 600 000
IU intramuscularly once per year.31 Serum 25[OH]D levels for vitamin D
associated with health benefit are listed in Table 3.
Treating deficiency involves correcting the vitamin D deficit and
ensuring continuing maintenance of vitamin D status. To normalise stores:
• adults require 3000–5000 IU/per day for 6–12 weeks9
• children aged <1 month require 1000 IU/day
Ultraviolet light also produces skin erythema, sunburn
(increasing melanoma risk), and cumulatively, skin aging and
increased nonmelanoma skin cancer risk. It is therefore important
to give nonconflicting public health messages as we promote
healthy behaviours (eg. skin protection, regular physical activity,
breastfeeding) and targets (eg. adequate vitamin D levels). For
incidental sun exposure (less than half the time required to produce
minimal skin erythema) it may be reasonable to omit sunscreen.9
Sunscreen sun protection factor 15 (adequately applied) reduces
previtamin D synthesis by >99%.4 Guidelines for adequate sun
exposure in Australia are summarised in Table 2.
Serum 25[OH]D levels show seasonal fluctuation, with peaks and
troughs at the end of summer and winter respectively. At latitudes
greater than 35 degrees, UVB energy is insufficient to produce vitamin
D during the winter months,4 producing a ‘vitamin D winter’ of variable
duration, centered on the winter solstice.3 During these times of
no cutaneous vitamin D production, dietary intake of vitamin D and
previous vitamin stores become important.
Vitamin D deficiency
Low 25(OH)D levels are termed ‘hypovitaminosis D’.1 When
combined with pathological abnormalities which are corrected by
physiological doses of vitamin D, the term ‘vitamin D deficiency’ is
used. Significantly low 25(OH)D levels can be termed ‘deficiency’
because of the known abnormal metabolic effects of low vitamin D
levels. Rarer conditions exist which require pharmacological doses
of vitamin D to overcome either reduced renal 1α-hydroxylase
activity or vitamin D receptor resistance. Vitamin D deficiency can be
classified as:
• mild (25–50 nmol/L)
• moderate (12.5–25.0 nmol/L), and
• severe (<12.5 nmol/L)
with levels of 50–100 nmol/L thought of as being vitamin D insufficient.
Table 2. Sun exposure guidelines
region October to March april to September
At 12:00 At 10:00 or 15:00 At 12:00 At 10:00 or 15:00
North (Townsville and Cairns) 2–5 minutes with extreme care 10 minutes with care 3–10 minutes with care 16 minutes with care
Central (Brisbane and Perth) 2–6 minutes with extreme care ~10 minutes with care 4–17 minutes with care 14–44 minutes with care or
extreme care in Brisbane
South (Adelaide, Sydney,
Melbourne, Hobart*)
2–10 minutes with extreme
care
15 minutes with extreme
care
5–34 minutes with care 21–60 minutes with care
Recommended solar radiation exposure to 15% of the body (face, hands, arms) at various times of the day and in various regions of Australia for fair skinned people to
produce vitamin D levels equivalent to current recommended daily intakes, assuming exposure occurs 3–4 times per week. Such exposures will give one-third minimal
erythema dose, and assumes average solar radiation intensity
Fair skinned = Fitzpatrick type II skin; care = sun protection is recommended if exposure is likely to exceed maximum recommended time; extreme care = sun protection is
highly recommended, as erythema can occur soon after maximum exposure time is exceeded
* Exposure times will be higher in Hobart (see citation for further details)
Adapted from: Samanek AJ, Croager EJ, Gies P, et al. Estimates of beneficial and harmful sun exposure times during the year for major Australian population centres.
Med J Aust 2006;184:338–41
1004 reprinted from auStralian FaMily pHySician Vol. 37, No. 12, December 2008
Page 4
Vitamin D – a review clinical practice
Arabia. Spine 2003;28:177–9.
12. Zittermann A. Vitamin D and disease prevention with special reference to cardio-
vascular disease. Prog Biophys Mol Biol 2006;92:39–48.
13. Harkness LS, Bonny AE. Calcium and vitamin D status in the adolescent: key roles
for bone, body weight, glucose tolerance, and estrogen biosynthesis. J Pediatr
Adolesc Gynaecol 2005;18:305–11.
14. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin
resistance and b cell dysfunction. Am J Clin Nutr 2004;79:820–5.
15. Schwalfenberg G. Not enough vitamin D – health consequences for Canadians. Can
Fam Physician 2007;53:841–54.
16. Feron F, Burne THJ, Brown J, et al. Developmental Vitamin D3 deficiency alters the
adult brain. Brain Res Bull 2005;65:141–8.
17. Liu PT, Stenger S, Li H, et.al. Toll-like receptor triggering of vitamin D-mediated
human antimicrobial response. Science 2006;311:1770–3.
18. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of
the vitamin D3 adequate intake versus 100mcg (4000 IU) per day on biochemi-
cal responses and the wellbeing of patients. Available at www.nutritionj.com/
content/3/1/8 [Accessed 29 April 2008].
19. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium sup-
plementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr
2007;85:1586–91.
20. Australian NHMRC and New Zealand Ministry of Health. Nutrient values for
Australia and New Zealand 2006. Available at www.nrv.gov.au/Nutrients.
aspx?code=30178006 [Accessed 3 July 2008].
21. Binkley N, Novotny D, Krueger T, et al. Low vitamin D status despite abundant sun
exposure. J Clin Endocrinol Metab 2007;92:2130–5.
22. Agus ZS, Drezner MK. Causes of vitamin D deficiency and resistance. UpToDate
2007. Available at www.utdol.com/utd/content/topic.do?topickey=minmetab/2045
0&view=print [Accessed 8 October 2007].
23. Aloia JF, Li-Ng M, Pollack S. Statins and vitamin D. Am J Cardiol 2007;100:1329.
24. Benson J. Hiding from the sun: vitamin deficiency in refugees. Aust Fam Physician
2007;36:355–7.
25. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and
inflammatory bowel disease. Gut 2000;46(Suppl I):i1–8.
26. Munns C, Zacharin MR, Rodda CP, et al. Prevention and treatment of infant and
childhood vitamin D deficiency in Australia and New Zealand: a consensus state-
ment. Med J Aust 2006;185:268–72.
27. Vieth R. Vitamin D supplementation, 25 hydroxyvitamin D concentrations, and
safety. Am J Clin Nutr 1999;69:842–56.
28. Vieth R. Critique of the considerations for establishing the tolerable upper intake
level for vitamin D: critical need for revision upwards. J Nutr 2006:1117–22.
29. Vieth R. Reply to J Hathcock and I Munro. Am J Clin Nutr 2001;74:862–7.
30. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin
Nutr 2007;85:6–18.
31. Diamond TH, Ho KW, Rohl PG, Meerkin M. Annual intramuscular injection of a
megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and
safety data. Med J Aust 2005;183:10–2.
32. Stein M. Vitamin D deficiency. Aust Fam Physician 2007;36:680.
33. Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose mater-
nal supplementation as therapy to prevent hypovitaminosis D for both the mother
and the nursing infant. Am J Clin Nutr 2004;80(Suppl):1752s–8.
• children aged 1–12 months require 3000 IU/day, and
• children aged >12 months require 5000 IU/day.26
Treatment is for 3 months, with adequate daily calcium.
An alternative of 1000 IU, three capsules/tablets three times per
day for 1 week then one capsule/tablet per day thereafter, with check
of serum 25[OH]D in 5 weeks and attention to adequate calcium intake
has been suggested.32
In practice, given the multiple interacting factors, it is appropriate to
treat vitamin D deficiency in adults with 2–3 months of supplementation,
checking the 25[OH] level and if satisfactory, rechecking the level at the
end of winter to ensure the trough is >100 nmol/L.3 The optimal interval
between retesting has not been established.
Future research
The extent to which initial interventional studies, epidemiological
associations and experimental studies are replicated will affect future
recommended vitamin D intake levels. The use of vitamin D as therapy
in infection, cancer and cell regulation is being increasingly explored.
The effect of vitamin D on mood and neurodevelopment and in primary
cancer prevention is also being studied.
Conflict of interest: none declared.
references
1. Parfitt AM, Gallagher JC, Heaney RP, et al. Vitamin D and bone health in the
elderly. Am J Clin Nutr 1982;36:1014–31.
2. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endo-
crine system essential for good health. Am J Clin Nutr 2008;88(Suppl):491s–9s.
3. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D
deficiency. Expert Opin Pharmacother 2008;9:107–18.
4. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes,
heart disease, and osteoporosis. Am J Clin Nutr 2004;79:362–71.
5. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 2006;92:4–8.
6. Visser M, Deeg D, Lips P. Low vitamin D and high parathyroid hormone levels
as determinants of loss of muscle strength and muscle mass (sarcopenia): the
Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88:5766–72.
7. Diamond T, Levy S, Smith A, Day P. High bone turnover in Muslim women with
vitamin D deficiency. Med J Aust 2002;177:139–41.
8. Megadose therapy for vitamin D deficiency. Med J Aust 2005;183:4–5.
9. Working group of the Australian and New Zealand Bone and Mineral Society,
Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and adult
bone health in Australia and New Zealand: a position statement. Med J Aust
2005;182:281–5.
10. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol)
supplementation on fractures and mortality in men and women living in the com-
munity: randomized double blind controlled trial. BMJ 2003;326:469–72.
11. Al Faraj SAI, Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi
Table 3. Levels of 25(OH)D producing health benefit
Beneficial effects of vitamin D Minimum serum 25(OH)D required
Prevent rickets/osteomalacia3 37.5 nmol/L
Dramatically suppress parathyroid hormone levels3 50–75 nmol/L
Optimise intestinal calcium absorption3 87 nmol/L
Optimise neuromuscular function3,5 60–87 nmol/L
Produce sufficient breast milk concentrations for infant health33 110 nmol/L (in one study)
Treatment of chronic musculoskeletal pain11 Treat identified deficiency
Suggested general target15 >100 nmol/L year round
CORRESPONDENCE afp@racgp.org.au
reprinted from auStralian FaMily pHySician Vol. 37, No. 12, December 2008 1005